ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Vaccitech raises $27 million for the flu

by Ryan Cross
January 22, 2018 | APPEARED IN VOLUME 96, ISSUE 4

Oxford University spin-off company Vaccitech has raised $27.1 million in series A funding to advance its universal flu vaccine and cancer vaccine programs. The flu vaccine, based on proteins conserved across all influenza A strains, is currently in a Phase IIb trial with over 800 people. Programs for four other infectious diseases are in various stages of development, and a Phase II trial for a prostate cancer vaccine will begin this year. Investors include GV (formerly Google Ventures), Sequoia China, Oxford Sciences Innovation, and Neptune Ventures.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment